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Abstract
Background: Variations in care models contribute to cancer pain being under-recognised and under-treated in half
of all patients with cancer. International and national cancer pain management guidelines are achievable with minimal
investment but require practice changes. While much of the cancer pain research over the preceding decades has
focused on management interventions, little attention has been given to achieving better adherence to recommended
cancer pain guideline screening and assessment practices. This trial aims to reduce unrelieved cancer pain by
improving cancer and palliative doctors’ and nurses’ (‘clinicians’) pain assessment capabilities through a targeted inter-
professional clinical education intervention delivered to participants’ mobile devices (‘mHealth’).
Methods: A wait-listed, randomised control trial design. Cancer and/or palliative care physicians and nurses employed
at one of the six participating sites across Australia will be eligible to participate in this trial and, on enrolment, will be
allocated to the active or wait-listed arm. Participants allocated to the active arm will be invited to complete
the mHealth cancer pain assessment intervention. In this trial, mHealth is defined as medical or public health
practice supported by mobile devices (i.e. phones, patient monitoring devices, personal digital assistants and
other wireless devices). This mHealth intervention integrates three evidence-based elements, namely: the COM-B
theoretical framework; spaced learning pedagogy; and audit and feedback. This intervention will be delivered via the
QStream online platform to participants’ mobile devices over four weeks. The trial will determine if a tailored mHealth
intervention, targeting clinicians’ cancer pain assessment capabilities, is effective in reducing self-reported cancer pain
scores, as measured by a Numerical Rating Scale (NRS).
(Continued on next page)
* Correspondence: jane.phillips@uts.edu.au
1University of Technology Sydney, PO Box 123, Ultimo, NSW 2007, Australia
Full list of author information is available at the end of the article
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Phillips et al. Trials           (2019) 20:62 
https://doi.org/10.1186/s13063-018-3152-z
(Continued from previous page)
Discussion: If this mHealth intervention is found to be effective, in addition to improving cancer pain assessment
practices, it will provide a readily transferable evidence-based framework that could readily be applied to
other evidence practice gaps and a scalable intervention that could be administered simultaneously to
multiple clinicians across diverse geographical locations. Moreover, if found to be cost-effective, it will help
transform clinical continuing professional development. In summary, this mHealth intervention will provide
health services with an opportunity to offer an evidence-based, pedagogically robust, cost-effective, scalable
training alternative.
Trial registration: Australian New Zealand Clinical Trials Registry (ANZCTR), ACTRN12618001103257. Registered
on 3 July 2018.
Keywords: MeSH terms, Cancer pain, Pain measurement, Assessment, pain, Health services research, Patient-
reported outcome measures, Palliative care, Clinical competence, Education, professional, Mobile applications,
Cost-benefit analysis
Background
Effective pain management cuts across professional
boundaries with clinicians’ failure to routinely screen
and assess for pain contributing to the burden of unre-
lieved cancer pain experienced by 39–66% of cancer pa-
tients [1]. To date, most research has focused on testing
new cancer pain treatments, with little attention payed
to strengthening cancer pain screening and assessment
practices. Evidence suggests that implementing routine
screening and assessment and managing pain in accord-
ance with evidence-based guidelines can improve quality
of care and outcomes for cancer pain [2–4].
Evidence of screening and assessment practices are in-
creasingly being recognised as quality indicators of opti-
mal cancer pain management internationally, with pain
now recognised as the fifth vital sign and routinely re-
corded on inpatients’ observation charts [5]. The sub-
jective nature of pain makes measuring patient-reported
outcomes the optimal source of clinical information [6].
However, instead of routinely seeking a patient-reported
Numerical Rating Scale (NRS) pain score, many clini-
cians adopt informal pain screening approaches [7] and/
or fail to comprehensively assess their patients’ pain [8,
9]. A survey of Australian patients receiving community
palliative care found that one-third experienced moder-
ate to severe pain, restricting their activities over the
preceding three days [10]. When this survey was re-
peated with a different cohort, a similar burden of unre-
lieved pain was reported [11].
It is recommended that a comprehensive pain assess-
ment be undertaken for all cancer patients with an NRS
pain score ≥ 2 [12, 13]. Determining the location, tem-
poral pattern(s), exacerbating and/or relieving factors
associated with the patient’s pain and ascertaining whether
the pain has nociceptive or neuropathic origin(s) [14] is in-
tegral to determining a differential pain diagnosis and an
individualised cancer pain management plan. Undertaking
a comprehensive pain assessment is complex and too few
clinicians have been formally taught how to assess across
these pain domains, with most learning ‘on the run’, by ob-
serving their peers or through industry events. Yet, clini-
cians’ cancer pain assessment competencies [15], their
understanding of the most suitable pain assessment tools,
commitment and capacity to integrate pain assessment
findings into clinical decision-making [16], communication
skills and capacity to address their patients’ care needs
within the context of multi-professional practice [17], all
impact on their patients’ pain outcomes.
Unfortunately, many interventions aimed at improving
clinicians’ pain assessment have had a limited effect on
cancer pain outcomes [18–25]. The reasons for this failure
are complex and varied and include failure to address the
multiple barriers at the patient (i.e. failing to report the
presence of pain), clinician (i.e. failing to adhere to recom-
mended routine pain screening and assessment practices)
[18] and organisational/system (i.e. accreditation and
funding not linked to meeting pain management stan-
dards) levels. Most previous clinician-targeted cancer pain
management interventions have been based on intuition,
as opposed to being theoretically driven [26], which in
part explains their ad-hoc success and limited transferabil-
ity [16]. While a small number of previous interventions
have focused on inter-professional education [18–23], not
all have optimised the educational intervention ‘dose’
(strength) [18–22] or effectively managed the complexity
of the intervention [20] and/or been underpinned by an
evidence-based behavioural change framework [26, 27].
Despite the complexity of undertaking a comprehen-
sive pain assessment, very few, if any, interventions have
targeted cancer pain assessment as a distinct learning
component, with most embedding screening and assess-
ment into a broader cancer pain management learning
package, privileging pharmacological cancer pain man-
agement practices [8]. In addition, few previous clinician
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targeted cancer pain management interventions have en-
gaged both doctors and nurses, with most focusing ex-
clusively on educating a single discipline as opposed to
inter-professional practices [19]. Yet, the interdisciplin-
ary nature of cancer and palliative care necessitates the
implementation of targeted inter-professional learning
strategies addressing pain assessment as a stand-alone
construct [19]. Given this reality, there are opportunities
to maximise the impact of any clinically focused cancer
pain assessment behavioural change intervention by in-
cluding evidence-based strategies, such as: (1) audit and
feedback, which includes any summary of clinical per-
formance over a defined period and can lead to poten-
tially important improvements in practice [28]; (2)
comprehensive interventions, which are more effective
when addressing patients’ pain, especially when docu-
mentation and monitoring interventions are combined
[18]; (3) more intense interventions involving extensive
follow-up, a comprehensive educational program and
greater resource allocation which are significantly more
likely to impact positively on reducing cancer pain [20];
and (4) explicit application of theory to identify context-
ual conditions necessary for their success and enhance
learning [26]. In addition, given the significant annual
investments healthcare organisations make towards
building clinical capabilities, few continuing professional
development (CPD) activities are underpinned by
evidence-based pedagogy and/or have been subjected to
an economic analysis.
These gaps highlight the need to develop and test al-
ternative strategies with a real potential to build cancer
and palliative care clinicians’ cancer pain assessment
capabilities, using effective and cost-effective pedagogic-
ally sound interventions underpinned by evidence-based
behavioural change theories [27].
The trial protocol reported here adheres to the Stand-
ard Protocol Items: Recommendations for Interventional
Trials (SPIRIT) checklist [29].
Objectives
Primary objective
To determine if a tailored mHealth intervention target-
ing clinicians’ cancer pain assessment capabilities is ef-
fective in reducing self-reported cancer pain scores, as
measured by a NRS.
Secondary objectives
To determine if the intervention:
i. increases clinicians’ adherence to the Australian
Cancer Pain Management in Adults Guidelines’
screening and assessment recommendations;
ii. increases the quality of clinicians’ pain assessment
documentation;
iii. increases clinicians’ cancer pain assessment capabilities
(knowledge and confidence); and
iv. is cost-effective compared with standard cancer and
palliative clinician CPD activities at reducing cancer
patients’ reported pain scores from a healthcare
systems perspective.
Trial design
The study will use a phase III wait-listed randomised
controlled trial (RCT) design, with individual cancer and
palliative care clinicians as the units of randomisation
(Fig. 1).
Design considerations
The design of the study is a simple RCT with all partici-
pants considered as the basic randomisation unit and
not nested in different sites. The justification for such
consideration was based on the following two observa-
tions made during the pilot study: (1) there was virtually
no cross-contamination among all participants, in that
they had no knowledge about each other’s study status;
and (2) there were no clustering characterisation across
different sites such that participants could be considered
as from a random sample [30]. Based on these observa-
tions, the study team opted to adopt the simple RCT de-
sign instead of a cluster RCT design.
Methods: participants, interventions and
outcomes
Study setting
Six palliative and/or cancer care centres in metropolitan
New South Wales (NSW), Australia will be involved in
the trial. Details about participating sites can be obtained




All participating sites must nominate a contactable ‘clin-
ical champion’ with whom the project team can liaise
directly.
Participants
All medical and nursing personnel (‘clinicians’) routinely
caring for cancer and/or palliative care patients at a par-
ticipating site are eligible to participate in the study. Par-
ticipants must be willing to give written informed
consent and be willing to participate in and comply with
the study policies and procedures.
Exclusion criteria
Sites
A competing trial that is enrolling cancer and/or pallia-
tive care clinicians.
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Participants
Agency and/or casual nurses or physicians who have
worked less than one shift in the month before the inter-
vention commences and unregistered health profes-
sionals who are unlikely to be undertaking and
documenting patients’ pain assessment.
Intervention
Intervention to be tested
A clinician-focused, spaced learning pain assessment
performance feedback intervention (‘intervention’) com-
bining: (1) an online spaced learning module delivering
authentic case-based cancer pain assessment scenarios
directly to participants’ mobile devices; (2) real-time
site-specific pain assessment audit and feedback, provid-
ing de-identified peer-to-peer comparisons; and (3) on-
line links to evidence-based pain assessment decision
supports.
Development of the intervention
The research team has undertaken a program of work [30,
31], underpinned by the Medical Research Council’s
(MRC) Framework [32] for complex interventions, to bet-
ter understand and address the cancer pain assessment
evidence practice gap. The development phase involved
an environmental scan, review of cancer patient reported
pain ratings, audit of cancer pain assessment practices and
development of a tailored mHealth intervention designed
to increase cancer and palliative care clinicians’ capacity to
effectively screen and comprehensively assess their pa-
tients’ cancer pain. This mHealth intervention integrates
several evidence-based elements, namely: (1) spaced learn-
ing; (2) audit and feedback and use of a clinical champion;
and (3) a theoretical framework (COM-B System) (Fig. 2).
Spaced learning
Learning encounters which are ‘spaced’ and ‘repeated
over time’ (‘spaced learning’) result in more efficient
learning and improved retention compared to the trad-
itional face-to-face bolus distribution learning format
[33, 34]. A recent systematic review has identified that
when delivered prospectively, spaced learning generates
significant topic-specific knowledge [35]. Spaced learn-
ing differs significantly from other pedagogies in that it
‘pushes’ short, clinically focused, case-based scenarios to
a participant’s email, which take ≤ 5 min to answer every
other day. Upon answering a question, a participant’s
de-identified performance is compared to that of their
peers and they are provided with succinct feedback and
links to relevant evidence-based resources and decision
supports. The spaced learning cancer pain assessment
case-based learning scenarios were developed by an ex-
pert panel comprising palliative and cancer care clini-
cians as well as education specialists, using the CASE
methodology, a systematic framework for generating
evidence-based, authentic case scenarios for learning
[36]. These case-based learning scenarios have been
tested in our pilot and feasibility studies [30, 31].
Audit and feedback
There is moderate evidence that auditing professional
practice and feeding back the results encourages greater
Fig. 1 Study flow chart
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adherence to professional standards and/or guidelines
[28]. A recent RCT demonstrated the value of integrat-
ing actual performance data into interventions designed
to change clinicians’ behaviour in a simulated environ-
ment [37]. The quality and safety data feedback, as part
of a spaced learning intervention, impacted positively on
US surgical residents’ knowledge retention and simu-
lated central line insertion performance [37]. While
there is ample RCT evidence that spaced learning can
improve knowledge acquisition and increase knowledge
retention from three months and up to two years [33,
34, 37]), there are no robust data that spaced learning
can impact positively on clinical practices outside of a
simulated environment [35]. In our intervention, real-time
site-specific pain assessment audit and feedback, providing
de-identified peer-to-peer comparisons will be integrated
into the spaced learning case scenarios. As there is good
evidence that audit and feedback is most effective when
provided by a supervisor or colleague (‘clinical champion’)
[28], the photo and a statement from the site-specific clin-
ical champion will also be integrated into the case sce-
nario feedback script. Participants will be provided with
hyperlinks to evidence-based pain assessment decision
supports.
Theoretical framework
The intervention is underpinned by the COM-B System
(Fig. 2), a framework for understanding and targeting be-
haviour change [27]. In this framework, capability, op-
portunity and motivations interact to generate the
desired clinical behaviour. In this study, clinicians’ cap-
abilities include having the necessary knowledge and
skills to routinely screen for pain and to proceed to
complete a comprehensive pain assessment if the patient
reports a NRS pain ≥ 3. Motivation energises and directs
clinician behaviour including conscious decision-making
about routine screening and assessing to make cancer
pain screening and assessment possible. Opportunity in-
cludes all factors that lie outside of the individual that
prompt clinicians to make cancer pain screening and as-
sessment possible (access to online decision prompts
and strategies for integrating pain assessment into usual
care). Adopting the evidence-based spaced learning
pedagogy adds strength to this theoretically driven
behaviour-change intervention. The Qstream™ platform
will be used to deliver the spaced learning case-based
cancer pain assessment scenarios and relevant site-spe-
cific pain assessment performance data.
Pilot testing
The piloting phase tested the acceptability of the spaced
learning intervention [30] and the feasibility of the pro-
posed RCT [31]. Our uncontrolled pilot demonstrated a
significant reduction in the mean patient-reported aver-
age daily numerically rated pain scores (0–10), between
the pre-post test audit, of 1.5 (95% confidence interval
[CI] = 0.7–2.3) [30]. In our pre-post test feasibility study,
a positive effect was observed in all measures in the
study. A larger adequately powered RCT is required to
confirm these results given these previous studies had
insufficient power to demonstrate statistical significance.
These pilot study results have informed the proposed
RCT sample size [30, 31]. This manuscript focuses on
the protocol for the evaluation phase, which aims to
Fig. 2 Applying the COM-B system to the CPAS trial
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determine if a tailored online spaced learning interven-
tion that increases clinicians’ cancer pain assessment
capabilities translates into a clinically significant reduc-
tion in cancer and palliative care patients’ NRS pain
scores.
Intervention arm
Consenting participants randomised to the intervention
arm will receive the intervention immediately (Fig. 3).
During the intervention, the participants will receive
four real-time site-specific pain assessment audit and
feedback data-related questions as well as eight case-
based cancer pain screening and assessment scenarios
(‘case studies’). The intervention will be delivered via
Qstream™, the online spaced learning platform. Each
case will be delivered directly to participant’s mobile de-
vices (via a free app) or email. Participants will receive
two case studies every second day, with each case taking
approximately 3–5 min to answer. Upon answering a
case, participants will receive: immediate de-identified
feedback on how they have performed compared to their
peers; and/or succinct audit and feedback data regarding
their sites pain screening or assessment practices, with
site-specific messages from local clinical champions.
They will also receive links to relevant evidence-based
resources and the Australian Cancer Pain Management
in Adults Guidelines decision support [12]. Correctly
answered cases will be re-sent after eight days, incor-
rectly answered cases will be re-sent every five days.
Cases will no longer be sent once they have been cor-
rectly answered twice. While the study period for each
participant will vary depending on how long it takes
them to complete the intervention, it is estimated that it
will take no longer than four weeks, as detailed in Fig. 3.
Control group
Consenting participants randomised to the wait-listed
control group will complete all of the data collection
measures but will not have access to the intervention
until the intervention arm participants at each site have
completed the trial and all data collection has been com-
pleted. It is anticipated that the control group partici-
pants will have access to the intervention within 16
weeks of the trial commencing at each site.
Adherence to intervention
Intervention adherence will be monitored weekly via
reporting analytics built into the QStream™ platform. All
participants will receive notification via their nominated
email and/or app, when a new case study is available to
answer, and/or if there are case studies awaiting their
completion. Weekly engagement reports will be gener-
ated via the Qstream™ platform to monitor participants’
progress. Participants who are not progressing through
Fig. 3 Standard Protocol Items Recommendations for Interventional Trials (SPIRIT) figure [5] showing the schedule of enrolment, interventions
and assessments for the Cancer Pain Assessment Study Trial
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the intervention as planned will be emailed directly and
offered online or face-to-face technical support, as re-
quired. Participants’ individual progress will remain con-
fidential and will not be disclosed to the participating
service; however, de-identified, weekly progress reports
will be sent to the each site’s nominated ‘clinical cham-
pion’ to identify the percentage of participants who have
enrolled and completed the intervention. The research
team will be available to assist participants with any
technical aspects of the intervention, such as app down-




The primary outcome measure will be at the patient
level and concern the probability that a tailored mHealth
performance feedback intervention will translate to a
clinically meaningful reduction in the mean change in
the pain NRS (0–10) scores, from admission to census
date. A cut-off of a two-point difference or 30% reduc-
tion in pain intensity on a NRS is considered to repre-
sent a clinically important difference [38].
As this is a pragmatic trial, all pain NRS scores will be
captured during the chart audit process from the pa-
tients’ medical records, thus negating the need for pa-
tient consent. The NRS is the optimal brief measure of
pain severity on the basis of compliance rates, respon-
siveness, ease of use and applicability; it is also recom-
mended by the Australian Cancer Pain Management in
Adults Guidelines [12]. The inter-rater reliability of the
chart auditors will be calculated using: Kappa statistics
for categorical variables; and the Bland–Altman method
of plots and limits of agreement for continuous variables
will be used to determine the degree of agreement be-
tween chart auditors [39]. A waiver of patient consent
has been authorised by the Human Research Ethics
Committee (HREC) to include documented de-identified
pain screening and assessment data from all patients re-
ceiving care from the participating units/sites during the
a priori defined audit periods at Times 1–3, to avoid se-
lection bias.
Secondary outcome measures
A range of secondary outcomes will be examined, in-
cluding clinicians’:
i. pain screening/assessment adherence scores;
ii. comprehensive pain assessment quality
documentation scores; and
iii. Self-Perceived Pain Assessment Capabilities (Self-PAC)
survey [40].
An economic evaluation will also be undertaken and
will include the following outcomes: efficacy measured
using the NRS pain scores, adherence scores and
Self-PAC scores; resource use, including the interven-
tion, i.e. clinician and administration time and Qstream
platform; and standard CPD, including clinician time.
Participant timeline
See Fig. 3 for the participant timeline.
Sample size
Informed by our pilot work [30, 31] and based on a
standard RCT design [41], it is estimated that a sample
size of 35 participants in each arm is required. This as-
sumes a 5% significance level and 90% power of the
study with an effect size of a reduction of mean
patient-reported pain rating of 1.5 (+ 2.0). Allowing for
an attrition rate of 25%, and 5% for possible inclusion of
covariates in the analyses, will increase the RCT sample
size to 90 clinicians (45 in each arm). To achieve the
trial objectives, it is estimated that 90 cancer and/or pal-
liative care clinicians, with half (n = 45) in each arm is
required.
Recruitment
Each participating site/unit will be invited to nominate a
‘clinical champion’ to act as the primary point of contact
with the research team. Clinical champions will provide
information about the study (Additional file 1) to all eli-
gible participants within their department and encourage
attendance at study information sessions conducted by
the research team.
Consent
All potential participants will be sent an email by the site
clinical champion inviting them to attend an information
session about the study, conducted by the research team.
This email will include the Participant Information and
Consent Form (Additional file 2) and information about
the Qstream™ mobile application (Additional file 3). At
the information session, participants will have the op-
portunity to discuss the study with a research team
member(s) before consenting. Consent will be under-
taken by a member of the research team. Upon consent-
ing, participants will be asked to provide their work
email address so a link to the baseline survey and
Qstream™ enrolment instructions can be sent to them.
Potential participants who are unable to attend the in-
formation session can contact the research team directly
before consenting. The consent process for all partici-
pants at all sites will be the same.
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Allocation
Participants will be sequentially allocated a unique iden-
tifying number (ID) on consenting to be involved with
the study. This ID number will consist of a two-digit site
number; a sequential three-digit number will be allo-
cated on randomisation of the participant. The full num-
ber sequence will be unique to that participant and will
not be reassigned. This ID number will be used for all
subsequent study documentation for that participant.
Each participant will be allocated to an intervention or
wait-listed control arm according to a randomisation
schedule generated by a central registry at the study
management centre (Bio-Statistician, LL). The central
registry will be responsible for generating the random-
isation tables and will provide the required number of
randomisation sequences in a spreadsheet or word docu-
ment. In order to avoid the difficulty of having imbal-
anced allocations, the permuted block randomisation
method will be employed with a block size of 6–8 and a
1:1 ratio of intervention to control. The allocation of the
randomisation codes will be managed by the study co-
ordinator. The participant ID, allocation code, com-
mencement and completion of the intervention surveys
will be recorded in a log maintained by the study
coordinator.
Blinding
Study investigators are blinded to participant allocation;
however, project officers collecting and managing the
data will not be blinded, as the frequency of documented
pain assessment between the intervention and control
groups is a secondary outcome measure in this RCT.
Methods: data collection, management and analysis
Data collection methods
Data will be collected at three time points during the
trial—Time 1 (T1), Time 2 (T2) and Time 3 (T3)
(Table 1)—as described below.
Chart audit data Patient-reported pain NRS scores and
clinicians’ adherence to pain screening and assessment
guidelines will be extracted from patients’ inpatient/
ambulatory care medical records (electronic and/or
paper-based). The chart audit tool developed, tested and
refined during the pilot studies will be adopted to ensure
standardised data collection. Medical records of all pa-
tients in the participating units, over 30 consecutive cal-
endar days, will be screened for audit at each study time
period (T1–T3). This will facilitate capturing chart audit
data within the same duration across all participating
units at each study time point. Documented patient-re-
ported pain NRS scores and guideline adherence data
will be collected by trained project officers.
Eligible medical records (chart audit) will include all
patients who during the three audit periods: (1) have a
primary diagnosis of cancer; 2) present for cancer treat-
ment at a participating centre and/or are referred to a
specialist cancer/palliative care service; and (3) have pain
at the time of first visit/appointment/admission or de-
velop pain during the audit period. In addition to cap-
turing patients’ basic demographics such as age, gender,
length of hospital stay, medical diagnosis, and cancer
and pain treatment(s), the chart audit will also capture:
patients’ pain scores on admission to the service; their
pain scores at discharge and/or audit date, depending on
which occurs first; clinicians’ documentation pain
screening/assessment actions; and whether the clinician
who documented the pain screening/assessment actions
was an intervention participant or non-participant (T2
and T3 only).
Chart audit data collected at baseline (T1) will be inte-
grated into the online learning intervention and tailored
to each service (see ‘Intervention’ above). At T2 and T3,
project officers will also record if pain screening/assess-
ment actions documented in the patient chart were under-
taken by an intervention participant or non-participant.
This will be determined by matching clinician signatures
in the patient chart with participant signatures on the
study consent form and cross-referencing participants
with the work roster for the audit period. To facilitate
identification of participants versus non-participants, pro-
ject officers undertaking the chart audits will not be
blinded to the group allocation. Documentation of partici-
pant versus non-participant on the chart audit tool will be
Table 1 Study activities at each time point
Study time




completion of the intervention
12 weeks after completion
of the intervention
Study activities
Chart audit data collection X X X
Online Participant Survey (Self-PAC Survey) X X
Economic data collection X X X
Wait-listed control group access online module X
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by way of a de-identified code only. No identifying partici-
pant details will be recorded on the chart audit tool.
Participant survey The Self-PAC survey has undergone
preliminary validation [40] and will be administered at
two study time points (T1 and T2) in an online format.
This instrument has three distinct sub-scales with Cron-
bach’s alpha reporting high internal consistency reliabil-
ity: seven-item pain assessment knowledge (0.944);
three-item pain assessment tool knowledge (0.846); and
seven-item pain assessment confidence (0.919) scales
[36]. To promote participant retention, project officers
will send a unique survey link to all participants and
send reminder emails to participants who do not
complete the survey within the required time frame, at
both survey time points.
Economic data Efficacy (pain NRS score; adherence and
Self-PAC scores) and resource use (intervention, i.e. clin-
ician and administration time, Qstream™ platform;
standard CPD, including clinician time) data will be col-
lected. CPD activity data will be collected via survey and
a pro-rata average cost per clinician calculated using the
annual CPD site allocation.
Data management
All hard copies from the study will be kept at the Centre
for Improving Palliative, Aged and Chronic Care
through Clinical Research and Translation (IMPACCT),
Faculty of Health, University of Technology Sydney,
Level 3, 235 Jones Street, Ultimo, NSW 2007. The elec-
tronic list of study codes with participant details will be
stored in the secure IMPACCT research drive and will
be password-protected. Hard copies of data will be se-
cured behind at least one locked door, within a locked
filing cabinet. Electronic records will be protected by a
password and the password will be changed at regular
intervals. Data will be stored for seven years. A dedicated
password protected REDCap account has been estab-
lished to deliver participant surveys for this study. This
account features enhanced security (SSL) and can only
be accessed by authorised members of the Research
Team. Survey data downloaded from the account will be
password-protected and stored on a computer hard
drive at IMPACCT in de-identified format. Once data
has been downloaded and de-identified, the correspond-
ing survey data will be deleted from the REDCap
account.
Confidentiality
The participant will be enrolled into the study after the in-
formed consent process has been completed. All consent-
ing participants will be given a unique Participant
Identification Code (ID). This will ensure that all
identifying data (e.g. email address) can be removed before
data analysis commences. This project ID will enable the
research team to manage the data in a confidential man-
ner. Participants are free to withdraw from the study once
it has started and can do so at any time without having to
give a reason. Withdrawal of consent will not affect partic-
ipants’ employment at their current work site. Previously
collected data may still be used in the analyses and partici-
pants will be advised it may not be possible to withdraw
their data from the study results. Where possible, the
reason for study withdrawal/non-completion will be
collected.
Statistical methods
Statistical analysis plan An intention-to-treat analysis
will be applied to all primary and secondary outcomes.
Missing data will be imputed using Multiple Imputation
by Chained Equations. Should an imbalance in clinicians’
characteristics be found between groups at baseline,
these characteristics will be included in the final analyses
as covariates. A significance level of 5% will be adopted
for refuting all test hypotheses. The intervention and
wait-listed control arms will be compared on the pri-
mary and secondary outcome measures.
The primary endpoint (reduction in mean pain NRS
scores) will be analysed using the Linear Mixed Method
with a repeated measures approach and possible adjust-
ments to patients’ and staff characteristics to compare
the mean change in patient pain NRS scores from ad-
mission to discharge or audit date between the interven-
tion and control groups across different time points.
The secondary endpoints will be analysed as follows:
i. The frequency of comprehensive pain assessment
between the intervention and control will be
determined by differences between groups. As
the outcome variable is a count variable without
a fixed bound, Poisson regression with possible
adjustments for covariates will be applied to the
data.
ii. A quality score will be calculated for each audited
record across time and entered into the patient’s
medical records. This score will reflect the quality
of the pain documentation in the medical notes and
will be calculated using seven items of documentation
(pain severity score, location, radiation, aggravating
and alleviating factors, quality and timing). One mark
will be assigned to an item identified in the medical
records and a summative quality score will then be
calculated to represent the total amount of
information recorded. A higher quality score
represents a larger amount of pain assessment
information recorded and a greater adherence to
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recommended pain assessment practices. The
quality of pain assessment documentation will
be determined by comparing the quality scores
across time and between groups using a General
Linear Model with repeated measures.
iii. The mean scores of the three domains of the Self-
PAC survey (pain assessment knowledge, pain
assessment tool knowledge and pain assessment
confidence) will be compared across time and
between the intervention and control groups using
the General Linear Model with repeated measures
approach and with possible adjustments for covari-
ates effects.
iv. The primary objective of the cost-effectiveness
analysis is to evaluate the incremental resource use,
cost and consequences of adding the mHealth
enabled pain assessment performance feedback
intervention to standard clinician CPD activities to
improve cancer pain control. A Markov decision
model will be developed to estimate the cost-
effectiveness of the mHealth intervention from a
healthcare perspective. Healthcare resource
utilisation and cost data will be estimated from a
systematic literature review of the direct and
indirect costs of pain in cancer patients including
hospitalisations, emergency department visits,
outpatient clinic appointments, medications, GP
visits and investigations. Responder rates will be
estimated from the project. The modelled economic
evaluation will provide estimates of the incremental
cost-effectiveness ratio (incremental cost per
additional responder, response = a 2-point mean
reduction in NRS pain score or 30% reduction in
pain intensity) and the incremental net monetary
benefit (INMB; monetary value of additional effects
of care minus the additional costs of care) [42] at
potential threshold values for responder rates and
cost-effectiveness acceptability curves. Model
sensitivity to variations in individual inputs and
overall decision uncertainty will be assessed through
probabilistic sensitivity analyses.
Interim analysis An interim analysis will be undertaken
immediately after 25 participants have completed the
intervention with data collected at T2. At this time, the
corresponding 25 clinicians in the control arm will also
be assessed for T2 data collection as described in the
protocol. The reasons for nominating a sample of 25 in
both intervention and control arms are: (1) based on the
concept that an interim analysis is recommendable at
the halfway point of the trial (i.e. half of the RCT sample
have completed the trial); (2) given that the total partici-
pants in each arm has been estimated to be 45, half of
the sample will only be about 22 clinicians. This sample
size would not be sufficient to support an accurate and
precise comparison between groups. To ensure sufficient
power for the interim analysis, a sample of 25 in each
arm is considered reasonable. In order to stop the trial,
we would need to demonstrate significant results of
comparison between groups with an effect size of a re-
duction in mean patient-reported pain rating by at least
1.5 units in the intervention arm at an alpha level of 5%
and preferably at 1%.
Methods: monitoring
Data monitoring
As this trial does not directly involve patients, or include
an intervention directed at patients, and there no ad-
verse events anticipated as a result of the mHealth inter-
vention, a data monitoring committee will not be
convened. If any issues should arise, they will be dealt
with at an extraordinary level through referral to an in-
dependent Trials Monitoring Committee.
Study monitoring/auditing
A study monitoring/auditing arrangement will be put in
place to ensure that patient privacy has been protected,
the study data can be verified and that the relevant ap-
provals were in place. The arrangement will include: (1)
regulatory approvals at each site are in place and filed ac-
cording to protocol; (2) participating clinicians’ identity
will be confirmed before study enrolment; (3) 10% of med-
ical record audits at each site, at each time point, will be
verified by a second auditor (project officer) to ensure
consistent and accurate data collection as well as adequate
protection of patient privacy; (4) project officers will rec-
ord if pain screening/assessment actions documented in
the patient chart were undertaken by an intervention par-
ticipant or non-participant (T2 and T3 only), documenta-
tion of participant versus non-participant on the chart
audit tool will be by way of a de-identified code only, i.e.
no identifying participant details will be recorded on the
chart audit tool; and (5) project officers to provide regular
reports to the Investigator team on recruitment, data col-
lection and any issues arising during these processes. Any
perceived/identified irregularities will be referred to an in-
dependent Trials Monitoring Committee.
Harms
No harms are foreseen for this trial due to the nature of the
intervention, which is an online learning module only and
not a medical intervention. However, it is acknowledged
that the intervention may evoke feelings of inadequacy or
discomfort associated with previous experience caring for
patients and/or their families with complex and/or poorly
managed pain. The online module will promote reflective
practice and adoption of best evidence-based pain assess-
ment and management practices. The research team will be
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available if participants wish to explore their previous expe-
riences and will refer participants onto appropriate support
services, if required.
Discussion
This trial will evaluate a targeted inter-professional mHealth
clinical education intervention designed to drive innovation
in cancer pain assessment. An adequately powered RCT is
required to confirm our pilot results and to determine if an
mHealth intervention that integrates spaced learning, audit
and feedback, and decision support prompts can reduce
cancer patients’ reported pain scores. A cost-effectiveness
analysis is also required to determine whether the interven-
tion represents value for money and should be promoted
more widely as a cost-effective evidence-based intervention.
Our proposed multicentred approach will increase the
strength of the study recommendations and extrapolation
of this intervention to other clinical settings.
If our phase III trial reports effectiveness, in addition
to improving cancer pain assessment practices, it will
provide an evidence-based framework (output) that
could readily be used to address other entrenched evi-
dence practice gaps (i.e. handwashing, managing the de-
teriorating patient and opioid prescribing). This
intervention is also scalable as its mHealth delivery for-
mat ensures that the intervention can be readily rolled
out across multiple services in diverse geographical loca-
tions. In the longer term, if the results are positive, they
will help transform the CPD paradigm from one focused
on random personal interests to one where clinicians’
learning experiences are aligned with identified clinical
practice gaps, ensuring that future CPD policy supports
learning experiences that improve patient care out-
comes. While mHealth initiatives are increasingly being
used, there is little research on which technologies or
pedagogical approaches are most effective in promoting
clinical practice behavioural change. There is even less
evidence around the cost-effectiveness of these CPD in-
terventions, hence the importance and timeliness of this
study. Given the scarcity of health resources, any inter-
vention designed to build clinicians’ pain assessment
capacity needs to be cost-effective [43]. Clinicians and
administrators can no longer afford to think of pain as
an inevitable consequent of living with cancer, but rather
view it as a modifiable factor that can be addressed
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